Compare BHP Billiton Limited (BHP) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BHP Billiton Limited vs Crispr Therapeutics AG — how do they compare? BHP Billiton Limited trades at $91.53 (market cap $229.15B), while Crispr Therapeutics AG trades at $54.31 (market cap $5.23B). The key difference: BHP Billiton Limited is far larger — about 43.8× Crispr Therapeutics AG's market cap, and BHP Billiton Limited pays a 2.95% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| BHP | CRSP | |
|---|---|---|
Market Cap | $229.15B | $5.23B |
Sector | Basic Materials | Health |
52-Week High | $93.15 | $76.78 |
52-Week Low | $52.14 | $44.34 |
Enterprise Value | $243.35B | $3.65B |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BHP trades at $90.61, up 0.22% with a bullish technical signal supported by moving averages. The company reported mixed Q4 2025 earnings, missing EPS estimates but maintaining strong profitability with 18.97% net margins. Recent operational challenges include strikes at Port Hedland iron ore operations, while copper production declines in Chile. Valuation metrics show a P/E of 22.36 and P/B of 4.54, reflecting premium pricing relative to historical levels.
The outlook remains cautiously optimistic with analyst consensus leaning hold (64.52%) amid labor disputes and production volatility. Key opportunities include exposure to AI-driven copper demand growth, while risks center on strike impacts and fluctuating commodity prices. The stock's current technical strength faces fundamental headwinds from operational disruptions.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BHP Billiton Limited
BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.
Read more on BHP →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
